The company, which specialises in the US healthcare market, saw statutory profit before tax jump by 52% to $24 million (c. £17.6m).

Total revenue for the year rose by 9% to $205.7m (c. £150m), while annual recurring revenue climbed 7% to $184m (c. £135m), supported by high customer retention rates of over 90 per cent. The firm’s adjusted EBITDA (earnings before interest, taxes, depreciation, and amortisation) increased by 12% to $65.3m (c. £48m), lifting its profit margin to 32%.

The robust performance has enabled Craneware to declare a final dividend of 18.5p per share, bringing the total for the year to 32p. This shareholder return is supported by a strengthened balance sheet, with the company’s cash position standing at $55.9m (c. £41m) alongside a reduction in bank debt to $27.7m (c. £20m).

Subsequent to the year-end, Craneware secured a new $100m (c. £73m) revolving credit facility on improved terms, which includes an additional $100m accordion option, providing further financial flexibility.

Chief executive Keith Neilson said: “Trading in the current year has started well, and with high customer retention rates, market leading offerings, specialist healthcare expertise and a significant proprietary data set, we have a strong foundation on which to build.”